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Abstract
Three heavy-chain and three kappa (κ)-chain transcripts were
amplified from hybridoma cells secreting a monoclonal
antibody (mAb) against transferrin receptor. Sequence
analysis via IMGT/V-QUEST yielded the functional/aberrant
prediction. Two functional κ-chain transcripts, Vκ2 and Vκ3,
and one functional VH1 were revealed. Comprehensive
bioinformatics analyses including sequence alignment,
phylogenetic tree, somatic hypermutation prediction, and
three-dimensional-molecular structure modeling were
used to predict the origin of the two κ-chain transcripts.
The results of bioinformatics analysis suggest that
Vκ3 is derived from the myeloma partner of the hybridoma;
Vκ2 is derived from B-cell. Functional transcripts VH1
and Vκ2 and Vκ3 were then used to construct two
chimeric antibodies chi-C2 (Vκ2–VH1) and chi-C3
(Vκ3–VH1), respectively. Antigen-binding experiments
showed that only chi-C2 remained the same affinity as its
parental mAb. Possible explanations for the coexistence of
two functional κ-chain transcripts and the different affinity of
the two chimeric antibodies are discussed. C© 2013 International
Union of Biochemistry and Molecular Biology, Inc. Volume 60, Number 3,
Pages 289–297, 2013
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1. Introduction
The transferrin receptor (TfR/CD71) is a cell-membrane-
associated glycoprotein involved in cellular uptake of iron and
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in regulation of cell growth. Additionally, it is a selective target
for cancer therapy [1–4]. We previously reported that a murine
monoclonal anti-human TfR antibody showed excellent anti-
tumor activity in vitro [5, 6]. However, because of the murine
monoclonal antibodies’ (mAbs) immunogenicity and poor abil-
ity to recruit immune effector mechanisms, the feasibility of
applying them in the clinic is limited. An attempt to over-
come these obstacles is to generate human–mouse chimeric
mAbs.
A prerequisite for the use of recombinant antibody tech-
nology from hybridomas or immune repertoires requires
reliable cloning of functional immunoglobulin genes. Amplify-
ing specific variable (V) regions of any given immunoglobulin is
challenging. A major problem is obtaining sequence informa-
tion about mAbs. The problem stems from the occurrence of
aberrant mRNAs, which are transcribed from rearranged, but
nonfunctional, heavy- and light-chain genes in the hybridoma
[7]. It is known that immunoglobulin genes are highly diverse
in their nucleotide sequences, as is the antibody repertoire
they encode. Genes encoding the V region of immunoglobulin
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TABLE 1
PCR primers used for amplification of Ig variable regions
Primer Primer sequence (5 ′–3 ′)
VL-f 1 GGGGTCGACCTCACCATGGAGACAGACACACTCCTGCTAT
VL-f 2 GGGGTCGACCTCACCATGGATTTTCAAGTGCAGATTTTCAG
VL-f 3 GGGGTCGACCTCACCATGGAG[A/T]CACA[G/T][A/T]CTCAGGTCTTT[G/A]TA
VL-f 4 GGGGTCGACCTCACCATG[G/T]CCCC[A/T][A/G]CTCAG[C/T]T[C/T]CTT/G]GT
VL-f 5 GGGGTCGACCTCACCATGAAGTTGCCTGTTAGGCTGTTG
VL-r 1 GCGGAATTCAGCCCGTTT[G/T]ATTTCCA[A/G]CTT
VH-f 1 GGGGTCGACCTCACCATGG[A/G]ATG[C/G]AGCTG[T/G]GT[C/A]AT[C/G] CTCTT
VH-f 2 GGGGTCGACCTCACCATG[A/G]ACTTCGGG[T/C]TGAGCT[T/G]GGTTTT
VH-f 3 GGGGTCGACCTCACCATGGCTGTCTTGGGGCTGCTCTTCT
VH-r 1 GGAAGATCTATAGACAGATGGGGGTGTCGTTTTGGC
VL-f, VL forward; VL-r, VL reverse; VH-f, VH forward; VH-r, VH reverse.
are assembled from rearrangement of three noncontiguous
gene segments, V, D, and J. Two-thirds of the time recom-
bination between variable segments induces a frameshift in
the open reading frame and the appearance of a premature
termination codon. This results in the formation of consid-
erable numbers of primary transcripts with out-of-frame V
regions [8].
The germline, junctional, and combinatorial diversity,
taken together with antigen-dependent changes such as hyper-
mutation and receptor-editing with B cell selection, can result
in the formation of a large number of diverse V-gene sequences.
The molecular identity of pathogen-specific V genes in novel hy-
bridomas is unknown and must be determined empirically via
cloning and sequencing. The V-gene sequence is the primary
sequence for encoding the antigen-binding-specific protein
domain and is useful for studying V-gene immunogenetics.
It is required for construction of the recombinant antibodies
used for therapy and diagnostics, patent disclosure, and clone
identity. Therefore, the nucleic acid sequence encoding the
V domain is of considerable importance [9]. Aberrant chains
derived from the myeloma partner of hybridomas may dilute
desired antibody sequences; these chains are the only ones
binding the antigen in a pool of nonproductive antibody-like
sequences [7,9].
On the basis of the above information, we ampli-
fied the heavy chain variable region (VH) and light
chain variable region (VL) transcripts obtained from a
hybridoma cell secreting anti-TfR mAb. Two chimeric
antibodies were formed using functional VL and VH
transcripts, and their antigen-binding properties were
examined.
2. Materials and Methods
2.1. PCR amplification and sequencing of murine VL
and VH genes from hybridoma
RNA was extracted from an anti-TfR mAb-secreting
hybridoma using Trizol reagent (Invitrogen, Shanghai,
China). cDNA was synthesized using a ReverTra Ace R© kit
(ToYoBo, Shanghai, China). The use of competitive V-gene PCR
rendered amplification straightforward. Amplification primers
VH-f1 to VH-f3 and VL-f1 to VL-f5 (Table 1) were designed to be
complementary to the mRNA flanking 5′ end of the constant CH
and Cκ regions of mouse immunoglobulin, respectively. Primers
VH-r1 and VL-r1 (Table 1) were designed to be complementary
to the antisense cDNA encoding the conserved N-terminal
region [10].
The PCR products were cloned into pGEM-T vector
(Promega, Fitchburg, WI, USA) and transformed in Escherichia
coli DH5α cells. Transformed cells were cultured on solid
Luria-Bertani medium containing 100 μg/mL ampicillin. cDNA
sequencing was performed by the Invitrogen Company.
2.2. Sequence analysis
The ExPASy translation tool was used to translate
DNA sequences to amino-acid sequences. The DNA se-
quences and amino-acid sequences were analyzed us-
ing IMGT/V-QUEST to identify functional VH and VL se-
quences and IMGT/DomainGapAlign to identify the V–J
region within the functional VH and VL sequences [11].
Alignment of amino-acid sequences was conducted us-
ing the CLUSTAL W2 program from EBI. Prediction of the
cleavage site and signal peptides was achieved using the
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TagetP 1.1 Server developed at the Technical University
of Denmark (http://www.cbs.dtu.dk/services/TargetP/) and
the SIG-Pred tool developed at the University of Leeds
(http://bmbpcu36.leeds.ac.uk/prot˙analysis/Signal.html).
A multinomial distribution model was used to deter-
mine whether the observed replacing mutations in any
given gene segment occurred by chance [12] (http://www
-stat.stanford.edu/immunoglobulin/).
2.3. Analyzing origins of variable light chains
NCBI/BLAST Blastn and blastp NIH programs
(http://blast.ncbi.nlm.nih.gov) were used to search for highly
similar DNA and protein sequences against all obtained light
chains separately. Because of the short length of the light
chains obtained, the megablast program was used when run-
ning blastn analysis. The psi-blast program was used when
running blastp analysis. Best matches were chosen by distance
tree view of the alignment results. MEGA5.05 was used for
building the phylogenetic tree.
2.4. Molecular modeling and protein structure
similarity analysis
Three-dimensional (3D) structures modeling and loop refine-
ment of corresponding proteins were analyzed using software
Insight II and SWISS-MODEL. The 3D structures of chimeric
single chain antibody fragment (scFv) were constructed by
homology modeling based on immunoglobulin VL and VH
domains containing highly similar amino-acid sequences and
known structures in PDB [13]. SWISS-MODEL web-based pro-
grams were used for comparison of the derived sequences to
identify the putative framework region (FR) and complemen-
tary determining region (CDR) loops in the variable genes of
TfR mAbs. The template modeling Score (TM)-align program
in the I-TASSER server was used to compare the predicted
structure similarity of Vκ2 and Vκ3.
2.5. Construction of chimeric anti-TfR antibody
(chi-TfR)
The mammalian expression vectors pFUSE-CHIg-hG1 (cat.code
pfuse2-hchg1) and pFUSE2-CLIg-hκ (cat.code pfuse2-hclκ),
each of which expresses human immunoglobulin constant re-
gions, were purchased from InvivoGen (San Diego, CA, USA)
and digested with restriction endonucleases. PCR products
were subcloned into the above descended expression vec-
tors to obtain pVκ-CLIg and pVH-CHIg, respectively. After
linearization with NotI, recombinant pVκ-CLIg and pVH-CHIg
were cotransfected into Chinese hamster ovary (CHO) cells
using Lipofectamine 2000 (Invitrogen). The cells were cul-
tured in 21 days, and the supernatants were harvested and
analyzed by enzyme-linked immunosorbent assay (ELISA) to
identify positive clones that produced human–mouse chimeric
antibodies. Two positive clones were obtained, chi-C2 and
chi-C3.
2.6. ELISA
A sandwich ELISA was designed to screen for clones producing
antibodies containing human IgG1 and kappa (κ) chain. Briefly,
the supernatants from the transfectants were diluted serially
from 1:5 to 1:3,125, and a suitable aliquoted 100 μL of each
supernatant was incubated at 4◦C with “captured” antibody,
goat anti-human κ chain (Southern Biotechnology Associates,
Birmingham, AL, USA), in wells overnight at 4◦C. After wash-
ing, 100 μL of horseradish peroxidase–labeled goat anti-human
immunoglobulin G (IgG) (γ -chain specific; Southern Biotechnol-
ogy Associates) was diluted to 1:1,000 and incubated at 37◦C
for 1 H. The optical density at 490 nm was determined with a
(Genios Tecan, Austria) ELISA plate reader. All positive clones
were retested to confirm a positive response.
2.7. SDS-PAGE
Samples were filtered through 0.45 mm filters and passed
through a HiTrap Protein A HP (GE Healthcare, Sweden) as per
the manufacturer’s instructions. Chimeric antibody samples
were analyzed by SDS-PAGE [4]. The gels were stained with
Coomassie Brilliant Blue R 250. Gels were visualized using a gel
image analysis system (Kodak Automatic Gel Imaging System,
Shanghai, China), and the images archived as digital graphic
files.
2.8. Flow cytometry analysis
The HL-60 (acute promyelocytic leukemia) cell was chosen
as the target cell for high expression TfR; 1 × 106 cells were
incubated at 4◦C for 1 H with supernatants from transfectants
expressing chi-C2 or chi-C3. The cells were washed (3×)
and incubated at 4◦C for 30 Min with fluorescein isothiocyanate
(FITC)-conjugated goat anti-human IgG antibody and examined
using a flow cytometer (Becton-Dickinson, San Jose, USA). In
addition, HL-60 cells were incubated with parental murine TfR
mAb. This treatment serves as a positive control. HL-60 cells
were maintained in Roswell Park Memorial Institute (RPMI)
1640 medium, and nonspecific IgG cells were used as blank
and negative controls, respectively.
2.9. Statistical analysis
Statistical significance of the data was calculated by analysis
of variance or Student’s t-test. A significance level of P < 0.05
was chosen.
3. Results
3.1. Sequence analysis
3.1.1. Functional sequences
Six DNA sequences were obtained after sequencing: three
sequences were amplified by VH primers, and three were
amplified by VL primers. Using IMGT/V-QUEST server with
a “mouse,” one functional heavy-chain gene (VH1) and two
functional light-chain genes (Vκ2 and Vκ3) were obtained
(Table 2).
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TABLE 2
Summary of IGMT analyses of obtained sequences
Sequence name Primer P/UNa V-gene and allele J-gene and allele IMGT analyses
VH1 VH-f1 P IGHV1S56*01 (93.06%) IGHJ3*01 (91.67%) Productive IGH rearranged sequence
VH2 VH-f2 UN IGHV5–17*02F (86.11%) No rearrangement found
Vκ1 VL-f1 UN IGκV3–12*01 (98.28%) IGκJ2*01 (100.00%) Unproductive IGκ rearranged sequence
Vκ2 VL-f2 P IGκV4–59*01 (98.19%) IGκJ2*03 (96.97%) Productive IGκ rearranged sequence
Vκ3 VL-f3 P IGκV6–17*01 (100.00%) IGκJ2*01 (94.74%) Productive IGκ rearranged sequence
aProductive (P), unproductive (UN).
FIG. 1
Sequences of anti-TfR VH region.
3.1.2. Cleavage site, FRs, and CDRs of VH1 sequence
The cleavage site of functional VH1 sequence is between amino-
acid residues 1 and 138. When compared with the closest genes
and alleles (Mus musculus IGHV1S56*01 and IGHJ3*01), three
CDRs and four FRs are found in VH1 as determined by IGMT
(Fig. 1).
3.1.3. Cleavage site, FRs, CDRs, and alignment of Vκ2
and Vκ3 sequences
Each of Vκ2 and Vκ3 contains 183 amino acids, three CDRs,
and four FRs. The cleavage site of Vκ2 is between positions 27
and position 28. The cleavage site of Vκ3 is between positions
25 and 26. Alignment of Vκ2 and Vκ3 amino-acid sequences
reveals that 79 amino acids (57%) of the total amino-acid
sequences are identical, whereas in Vκ2 the V segment and
J segments are rearranged and lack an amino-acid residue
between them. Two amino-acid residues occur between the
V segment and J segment in Vκ3 (Fig. 2).
3.2. Somatic hypermutation and antigenic selection
Statistical analysis was used to establish the types (e.g., silent
or amino acid replacing) and distribution in the CDRs or FRs
of somatic mutations. Twenty mutations were detected in the
functional VH1 transcript (data not shown). As with the VL
transcript, seven mutations were found in the Vκ2 gene, one
silent mutation in FR1, one nonsilent mutation in FR2, three
nonsilent mutations in FR3, and two nonsilent mutations in
CDR3. No somatic mutation was found in the Vκ3 gene as
predicted (Fig. 3). It strongly suggests that the VH1 and Vκ2
transcripts were subjected to antigenic selection.
3.3. Blast alignment of light chains
Using PSI-BLAST searching on BLASTP suit/BLAST/NCBI with
significant E-value (<1e−40) and high total score (>140), more
than 200 similar sequences were found for each light chain.
According to the distance tree generated from the results
provided by BLAST/NCBI, the Vκ protein sequence maps
to an aberrant κ transcript from mouse MOPC21 cell line
(PIR:JL0073) with zero distance. The Vκ3 protein sequence is
branched with κ-chain V–V region from MPC11 (SP:P01633.1),
whereas the Vκ2 protein sequence is branched with many
single-chain antibodies (Table 3).
The Vκ1 protein sequence exhibits 100% identity with
the sequence PIR:JL0073. This result confirms that Vκ1 is the
aberrant sequence arising from the myeloma partner MOPC21
of the hybridoma cell line. Vκ2 and Vκ3 are new sequences. No
identical sequence is yet to be found in the NCBI database.
3.4. Phylogenetic trees
Two phylogenetic trees have been built using light-chain DNA
sequences and amino-acid sequences. Highly similar DNA
sequences (2–3) from BLAST alignment results for each light
chain were used to construct the phylogenetic tree (Fig. 4A).
These results show that Vκ1 and Vκ3 are closer than Vκ2.
Because the amino-acid sequence of Vκ3 exhibits a greater
homology to a κ chain of MPC11, we used the protein sequences
of MPC11 and MOPC21 and Vκ2 and Vκ3 to construct an amino
acid phylogenetic tree (Fig. 4B). The results indicate that Vκ3
is more closely related to MPC11; each of them was grouped
with MOPC21 but not Vκ2.
Combining the two phylogenetic trees’ results, we sug-
gest that Vκ3 but not Vκ2 is a myeloma-derived light-chain
sequence.
3.5. 3D models of chimeric scFvs and protein structure
comparison
A 3Dmodel of the variable domains showed that fragment, anti-
gen binding region (Fab) of TfR mAb had complete functional
domains as well as binding grooves involved in the composition
of the hydrophobic pocket (Fig. 5).
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FIG. 2
Alignment of amino-acid sequences of anti-TfR
mAb Vκ2 transcript and Vκ3 transcript. Pink
highlight denotes signal peptide, blue highlight
denotes FR, and yellow highlight denotes CDR.
Red letters denote J segment sequence.
Crossed-out letters denote residues between the
V and J segments.
The TM these two models is 0.59. These results strongly
suggest that the two chimeric scFvs are nearly or fully identical.
3.6. Expression and purification of chimeric antibody
The supernatants of transfected CHO cells incubated for
5–7 days were collected and purified by binding to Protein
A-sepharose. The purified products were diluted and detected
by SDS-PAGE. Heavy and light chains of the expected molecular
weights, 60 and 30 kDa, were observed under denaturing
conditions (Fig. 6).
3.7. Binding capability of chimeric antibody
IgG of human origin was used as a standard to construct a
standard curve to control to quantify chi-C2 and chi-C3. The
concentration of chi-C2 and chi-C3 was calculated as 32 and
26 μg/mL, respectively.
Flow cytometry (FCM) results reflect the binding strength
by binding rate of the antibody-targeted recognition with TfR-
positive tumor cells. The antigen-binding rate of parental
murine mAb, chi-C2, and Chi-C3 was 69.68 ± 13.47%,
48.47 ± 15.2%, and 14.87 ± 16.24%, respectively. Each value
is significantly higher than the negative control (P < 0.05).
The binding rate of chi-C3 (14.87 ± 16.24%) was significantly
lower than those of chi-C2 and parental murine mAb (P < 0.05)
(Fig. 7). No significant difference was found between parental
murine mAb and chi-C2. This finding suggests that chi-C2 re-
tains the antigen-binding ability of its corresponding parental
mAb. chi-C3 has a very weak antigen-binding ability, and it is
significantly lower than chi-C2 and parental mAb.
4. Discussion
In these experiments, one B-cell–derived κ transcript (Vκ2)
and two myeloma-derived κ transcripts (Vκ1 and Vκ3) were
amplified from one hybridoma that secreted anti-TfR mAb.
One κ transcript, Vκ1, remained aberrant, but the other, Vκ3,
FIG. 3
Mutated IGVκ sequences analyzed by
http://www-stat.stanford.edu/immunoglobulin/.
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TABLE 3
Blast alignment of light chains
Sequence name Part of the tree generated from PSI-BLAST result
Vκ1
Vκ2
Vκ3
FIG. 4
(A) DNA sequence phylogenetic tree of light chains
and (B) amino-acid sequence phylogenetic tree of
light chains.
contains a rearranged functional light chain. Many investiga-
tors, including ours, have amplified the myeloma-derived κ by
RT-PCR while attempting to clone the functional light chain
from the B-cell fusion partner of hybridomas [9,14–16].
Distinguishing the functional gene derived from the fused
B cell and the myeloma-derived κ transcript has been problem-
atic. A hybrid approach has been used to analyze the three κ
chains, that is, we combined the “dry” bioinformatics evidence
together with “wet” experimental evidence. Bioinformatics
analyses provided the theoretical hypothesis that two κ chains
may derive from a myeloma ancestor. The antigen-binding
experiment gave us the physical evidence to confirm the hy-
pothesis inferred by informatics. IMGT analysis yielded the
most reliable prediction in immune genes. To avoid bias and
provide solid theoretical evidence, the sequence alignment was
of importance. There are more than 15 million records in the
Genebank n/r database, and the number is growing daily. The
short length of obtained κ chains (∼130 in terms of amino acid
and ∼380 bp in terms of their nucleotide sequence), using a
normal blast algorithm allowed us to findmore than 150 similar
sequences (e.g., using blastn retrieved 170 sequences similar
to the Vκ3 nucleotide sequence). It is difficult to characterize
light-chain sequences using this approach. Therefore, in these
studies, we applied Mega-BLAST for determining nucleotide
sequences, PSI-BLAST for amino-acid sequences, and com-
bined the Blast tree view to select the most similar sequences
from the results (∼120 sequences). This allowed filtering out
one-third of the total results using the normal BLAST program.
Phylogenetic trees built from amino-acid sequences and nu-
cleotide sequences support the hypothesis that Vκ3 and Vκ1
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FIG. 5
Computer-assisted modeling of Fab of TfR mAb
(A: chi-C2 Fab region and B: chi-C3 Fab region). A
model of anti-TfR VH and Vκ is shown as blue
backbone. The β-layer secondary structures of VH,
VL, and CDR1–3 are depicted in yellow.
are of the same myeloma origin and they are closer to MPC11
or MOPC21. In addition, multiple mutations are predicted in
Vκ2 but not in Vκ3. The results support the hypothesis that
Vκ2, but not Vκ3, was subjected to antigen selection.
Why does the transcript Vκ3 exist in the hybridoma that
secreted anti-TfR mAb, and why is its origin much closer to
MPC11? First, most mouse myeloma cell lines available for
fusions are descendants of either MPC11 BALB/c myeloma
or MOPC21 BALB/c myeloma lines [16]. The anti-TfR mAb-
secreting hybridoma cell line’s myeloma partner may come
from a fusion of MPC11 and MOPC21. Brady et al. found two
MOPC-derived κ transcripts in their murine MOPC21-derived
hybridomas. One is identical to the full-length κ chain of MPC11,
and the other is the MPC11 aberrant κ transcript, which has
no variable region [17]. Second, hybridomas are stable in
culture and continue to produce the same antibody indefinitely.
However, rare mutant clones, which produce an antibody that
has changed its specificity, affinity, class, or subclass, can arise
[18]. The existence of transcript Vκ3may be due to themutation
or contamination of the hybridoma cell line. Last, although two
functional κ transcripts have been amplified, the mentioned cell
line secretes only one type of mAb. It seems possible that the
two light chains exist at the transcript level but only one light
chain is secreted in our hybridoma. For example, in the case
of hybridoma CEA 66-E3, only one Ab is secreted, although it
contains significant levels of multiple Ig transcripts.
The major problem in rapidly obtaining chain variable
genes from a hybridoma is the occurrence of aberrant mRNAs
that can be transcribed but that have no function. If the
aberrant gene is used in the construction of the chimeric or
humanized antibody, it may produce immunoglobulin that has
low affinity for the antigen and is completely nonfunctional
[19]. We encountered such a situation in our experiments.
Although structure simulation shows that chi-C2 and chi-
C3 are very similar in the protein structure level, their actual
affinity functions are different. This could be attributed to the
different origins of Vκ2 and Vκ3. However, when compared
FIG. 6
Expression and purification of chimeric antibody.
The purified chimeric antibody was identified by
12% SDS-PAGE and stained with Coomassie
Brilliant Blue R250. Molecular weight markers are
indicated.
with the negative control, chi-C3 still possesses a weak affinity,
which is significantly lower than chi-C2. Because chi-C3 was
constructed with functional VH and Vκ3, the functional VH1
chain may responsible for the weak affinity of chi-C3.
Several strategies may decrease the amplification of
aberrant variable genes, but they have limitations primarily
because the aberrant genes may be highly homologous to the
functional ones. As a result, the more information we have
about the aberrant genes, the higher efficiency of functional
gene amplification we can obtain and the better we can avoid
the aberrant genes in antibody engineering.
In our experiment, two aberrant VH genes may arise from
an unproductive transcript in myeloma cells, a rearranged
transcript in B cells, or a gene mutation in a fusion of the two
kinds of cells. After the analysis, we found the two unpro-
ductive heavy chains were also very prevalent in the study of
hybridoma, and found that it has a high similarity with Ig heavy-
chain V region MOPC21, a previously described aberrantly
rearranged heavy-chain gene (GenBank accession no. X58634)
believed to be derived from the fusion partner P3×63-Ag8.653.
Aberrant VH genes are less often reported but are more
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FIG. 7
The antigen-binding ability of chi-TfR Ab to the TfR
expressed on HL-60 cells. Data were represented
as the means ± SD of three independent
experiments. A significance level of P < 0.05 was
chosen. *P < 0.05, **P < 0.01, and ***P < 0.001.
complicated and not as widely recognized as that of the
MOPC21κ allele [19,20].
More than two different variable genes in one hybridoma
were rare. At first, we did not place any significance on
aberrantly VH genes, and two functional Vκ chains stimulated
our interest. The sequence alignment, phylogenetic tree,
somatic hypermutation prediction, and 3D-molecular structure
modeling were used to predict the origin of the two κ-chain
transcripts. The experimental evidence of chi-C2 and chi-C3
in accordance with bioinformatics evidence showed that Vκ3
is derived from the myeloma partner of the hybridoma; and
the Vκ2 is derived from the B cell. These results encouraged
us to analyze the sources of two aberrantly VH genes, the
distinct innate MOPC21H allele genes gave us more evidence
to support our result. Another attempt is to find simple and
effective methods to identify functional and aberrant genes. We
did a restriction-enzyme polymorphism analysis on aberrant
VL gene (Vκ1), functional gene (Vκ2), and the myeloma-likely-
derived Vκ3 gene. The results show that Vκ1 has BciVI site, but
not Vκ2 and Vκ3. Only Vκ2 has many restriction-enzyme sites,
such as BamHI, HindIII, EcoRI, KpnI, and XbaI, but not Vκ1 and
Vκ3. The same analysis was done with nonfunctional heavy
chains. We found that two nonfunctional heavy chains have
62 identical restriction-enzyme sites, and then based on these,
we chose every two VH chains from 16 families of VH1–16 of
mouse IgH V germline sequences, and found these families and
two aberrant VH have many identical restriction-enzyme sites.
These results showed that enzyme sites, such as BsmBI, Esp3I
DraII, PpuMI, Psp5II, and EcoO109I, may be used to distinguish
the innate VH of MOPC21.
In addition, some investigators suggest that if a hybridoma
expresses a variety of variable region genes, only one advantage
light-chain and heavy-chain antibody genes are fully functional,
whereas others will lose their functionality [17]. This situation
may explain the phenomenon reported in this article.
5. Conclusions
In this study, we report that two distinct functional κ-chain
transcripts were present in all the transcripts amplified from a
hybridoma that secretes anti-TfR mAb. Coexistence of distinct
light transcripts from a single hybridoma is not uncommon.
A few previous studies have demonstrated the coexistence of
functional κ-chain transcripts. However, when using functional
κ-chain transcripts to construct chimeric mAbs, apparently only
one light transcript is involved in the formation of a functional
chimeric mAb that has an affinity similar to the mAb secreted
from the hybridoma. In-depth combined bioinformatics analysis
based on sequence information is needed before constructing
a mAb. The approach used in this study establishes a standard
workflow for constructing mAbs in our laboratory, as well
as a reference workflow for any other antibody engineering
laboratories. ThemAbwas amplified using degenerate primers,
and the primers more frequently amplified were analyzed for
nonfunctional sequences. For example, primers Vκ1, VH2, and
VH3 are reliable for obtaining aberrant chains; the primer
sequences show some continuous sequences are identical
with endogenous genes of MOPC21. We deleted these primers
and subsequent amplification was relatively easy. Finally,
it is evident that at the primer design stage, the primers
amplifying the VH2, VH3, Vκ1, and Vκ3 sequences should be
filtered out.
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